| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft vs Host Disease | 101 | 2025 | 503 | 15.950 |
Why?
|
| Cyclophosphamide | 83 | 2023 | 412 | 14.470 |
Why?
|
| Bone Marrow Transplantation | 60 | 2023 | 564 | 9.530 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 55 | 2024 | 1097 | 8.560 |
Why?
|
| Transplantation Conditioning | 49 | 2023 | 279 | 7.270 |
Why?
|
| Immunosuppressive Agents | 36 | 2022 | 645 | 6.090 |
Why?
|
| Hematologic Neoplasms | 31 | 2023 | 277 | 5.660 |
Why?
|
| Leukemia, Myeloid, Acute | 21 | 2024 | 520 | 4.170 |
Why?
|
| Transplantation, Haploidentical | 15 | 2020 | 16 | 4.080 |
Why?
|
| Transplantation, Homologous | 50 | 2024 | 621 | 3.630 |
Why?
|
| HLA Antigens | 22 | 2020 | 238 | 2.990 |
Why?
|
| Tissue Donors | 21 | 2023 | 483 | 2.150 |
Why?
|
| Unrelated Donors | 15 | 2023 | 67 | 1.990 |
Why?
|
| Histocompatibility Testing | 21 | 2020 | 144 | 1.650 |
Why?
|
| T-Lymphocytes, Regulatory | 6 | 2016 | 216 | 1.350 |
Why?
|
| Antilymphocyte Serum | 3 | 2019 | 55 | 1.270 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2024 | 395 | 1.260 |
Why?
|
| T-Lymphocytes | 18 | 2023 | 1720 | 1.250 |
Why?
|
| Stem Cell Transplantation | 7 | 2017 | 235 | 1.210 |
Why?
|
| Antineoplastic Agents, Alkylating | 8 | 2017 | 101 | 1.140 |
Why?
|
| Tacrolimus | 5 | 2021 | 97 | 1.120 |
Why?
|
| Myeloablative Agonists | 5 | 2021 | 15 | 1.120 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2023 | 774 | 1.120 |
Why?
|
| Haplotypes | 8 | 2016 | 521 | 1.030 |
Why?
|
| Histocompatibility | 13 | 2020 | 47 | 1.010 |
Why?
|
| Myelodysplastic Syndromes | 6 | 2021 | 125 | 0.970 |
Why?
|
| Humans | 137 | 2024 | 125356 | 0.950 |
Why?
|
| Allografts | 11 | 2018 | 176 | 0.950 |
Why?
|
| B-Lymphocytes | 8 | 2022 | 532 | 0.940 |
Why?
|
| Major Histocompatibility Complex | 3 | 2017 | 51 | 0.940 |
Why?
|
| Recurrence | 21 | 2023 | 1394 | 0.940 |
Why?
|
| Lymphoma | 6 | 2021 | 318 | 0.930 |
Why?
|
| Middle Aged | 65 | 2023 | 26763 | 0.900 |
Why?
|
| Transplantation Chimera | 11 | 2016 | 37 | 0.850 |
Why?
|
| Immune Reconstitution | 2 | 2022 | 6 | 0.830 |
Why?
|
| Killer Cells, Natural | 3 | 2022 | 327 | 0.810 |
Why?
|
| Adult | 64 | 2023 | 29543 | 0.790 |
Why?
|
| Immune System Diseases | 1 | 2022 | 47 | 0.780 |
Why?
|
| Calcineurin Inhibitors | 1 | 2021 | 29 | 0.740 |
Why?
|
| Aged | 47 | 2021 | 19722 | 0.720 |
Why?
|
| Ursidae | 1 | 2020 | 2 | 0.710 |
Why?
|
| Young Adult | 32 | 2023 | 9061 | 0.710 |
Why?
|
| Immune Tolerance | 3 | 2023 | 144 | 0.700 |
Why?
|
| Chronic Disease | 18 | 2025 | 1189 | 0.700 |
Why?
|
| Disease-Free Survival | 16 | 2021 | 880 | 0.700 |
Why?
|
| Male | 70 | 2024 | 61565 | 0.690 |
Why?
|
| Chimerism | 2 | 2019 | 28 | 0.680 |
Why?
|
| Leukemia | 4 | 2021 | 367 | 0.670 |
Why?
|
| Bone Marrow | 9 | 2022 | 323 | 0.650 |
Why?
|
| Bone Marrow Cells | 2 | 2016 | 262 | 0.650 |
Why?
|
| Bronchiolitis Obliterans | 7 | 2022 | 40 | 0.650 |
Why?
|
| Methotrexate | 1 | 2021 | 336 | 0.650 |
Why?
|
| Lymphocyte Activation | 9 | 2019 | 700 | 0.640 |
Why?
|
| Aldehyde Dehydrogenase | 2 | 2022 | 41 | 0.630 |
Why?
|
| Female | 71 | 2024 | 66820 | 0.620 |
Why?
|
| Busulfan | 2 | 2015 | 41 | 0.610 |
Why?
|
| Biomarkers | 4 | 2018 | 3106 | 0.600 |
Why?
|
| Cell Differentiation | 2 | 2024 | 1909 | 0.580 |
Why?
|
| Whole-Body Irradiation | 6 | 2019 | 60 | 0.580 |
Why?
|
| Chemoprevention | 2 | 2016 | 58 | 0.570 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2018 | 46 | 0.570 |
Why?
|
| Graft Survival | 7 | 2016 | 532 | 0.550 |
Why?
|
| Germinal Center | 4 | 2022 | 38 | 0.550 |
Why?
|
| Immunomodulation | 3 | 2020 | 79 | 0.550 |
Why?
|
| Cancer Vaccines | 3 | 2019 | 177 | 0.540 |
Why?
|
| Immunologic Factors | 3 | 2020 | 173 | 0.540 |
Why?
|
| Treatment Outcome | 31 | 2024 | 12287 | 0.540 |
Why?
|
| Anemia, Aplastic | 4 | 2023 | 57 | 0.530 |
Why?
|
| T-Lymphocyte Subsets | 7 | 2022 | 199 | 0.520 |
Why?
|
| Mice, Inbred BALB C | 12 | 2020 | 1002 | 0.520 |
Why?
|
| Survival Analysis | 12 | 2019 | 1495 | 0.510 |
Why?
|
| Mice | 32 | 2025 | 17750 | 0.500 |
Why?
|
| Animals | 39 | 2025 | 34319 | 0.500 |
Why?
|
| Vidarabine | 6 | 2014 | 77 | 0.500 |
Why?
|
| Graft vs Leukemia Effect | 3 | 2020 | 28 | 0.480 |
Why?
|
| Transplantation Tolerance | 2 | 2016 | 15 | 0.480 |
Why?
|
| Graft vs Host Reaction | 4 | 2008 | 9 | 0.470 |
Why?
|
| Acute Disease | 9 | 2022 | 1097 | 0.470 |
Why?
|
| Dendritic Cells | 2 | 2009 | 414 | 0.470 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 2025 | 80 | 0.460 |
Why?
|
| Leukemia, Myeloid | 1 | 2014 | 81 | 0.450 |
Why?
|
| Drug Monitoring | 1 | 2015 | 171 | 0.450 |
Why?
|
| Lymphocyte Transfusion | 4 | 2013 | 55 | 0.430 |
Why?
|
| Lymphoma, B-Cell | 3 | 2015 | 140 | 0.420 |
Why?
|
| Immunotherapy | 6 | 2022 | 678 | 0.420 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 3 | 2019 | 32 | 0.410 |
Why?
|
| Adolescent | 26 | 2023 | 19429 | 0.400 |
Why?
|
| Lung Transplantation | 1 | 2016 | 323 | 0.400 |
Why?
|
| STAT3 Transcription Factor | 2 | 2016 | 218 | 0.390 |
Why?
|
| Antineoplastic Agents | 6 | 2018 | 1714 | 0.380 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2019 | 817 | 0.370 |
Why?
|
| Haploidy | 3 | 2016 | 19 | 0.370 |
Why?
|
| Lymphocyte Depletion | 5 | 2016 | 121 | 0.370 |
Why?
|
| Mice, Inbred C57BL | 15 | 2025 | 4423 | 0.370 |
Why?
|
| Hypertension | 1 | 2019 | 1332 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2021 | 1244 | 0.350 |
Why?
|
| Time Factors | 9 | 2021 | 6311 | 0.350 |
Why?
|
| Isoantibodies | 3 | 2018 | 72 | 0.340 |
Why?
|
| Sirolimus | 2 | 2013 | 227 | 0.330 |
Why?
|
| Hodgkin Disease | 4 | 2020 | 290 | 0.320 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2014 | 471 | 0.320 |
Why?
|
| Lymphocytes | 3 | 2019 | 408 | 0.320 |
Why?
|
| Immune System | 2 | 2009 | 90 | 0.320 |
Why?
|
| Clinical Trials as Topic | 5 | 2018 | 1104 | 0.310 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 2 | 2022 | 13 | 0.310 |
Why?
|
| Scleroderma, Systemic | 1 | 2009 | 117 | 0.300 |
Why?
|
| Neoplasms, Experimental | 1 | 2009 | 216 | 0.300 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2009 | 264 | 0.300 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2008 | 20 | 0.300 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2007 | 160 | 0.290 |
Why?
|
| Immunophenotyping | 5 | 2022 | 327 | 0.290 |
Why?
|
| Remission Induction | 8 | 2020 | 292 | 0.280 |
Why?
|
| Retrospective Studies | 19 | 2023 | 16369 | 0.280 |
Why?
|
| Immunologic Memory | 3 | 2024 | 190 | 0.270 |
Why?
|
| Langerhans Cells | 1 | 2006 | 21 | 0.260 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2022 | 832 | 0.250 |
Why?
|
| Proteomics | 2 | 2022 | 506 | 0.250 |
Why?
|
| Interleukin-10 | 1 | 2007 | 174 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2016 | 1065 | 0.250 |
Why?
|
| Cytarabine | 3 | 2021 | 95 | 0.250 |
Why?
|
| Disease Models, Animal | 10 | 2020 | 4409 | 0.250 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2025 | 14 | 0.240 |
Why?
|
| DNA Demethylation | 1 | 2025 | 8 | 0.240 |
Why?
|
| Prospective Studies | 10 | 2023 | 6141 | 0.240 |
Why?
|
| Dioxygenases | 1 | 2025 | 46 | 0.230 |
Why?
|
| Immunoglobulin G | 3 | 2025 | 780 | 0.230 |
Why?
|
| Multiple Myeloma | 2 | 2017 | 138 | 0.230 |
Why?
|
| Lymphocyte Culture Test, Mixed | 3 | 2013 | 41 | 0.230 |
Why?
|
| Graft Rejection | 5 | 2018 | 588 | 0.230 |
Why?
|
| Nucleotidyltransferases | 1 | 2024 | 43 | 0.220 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2024 | 43 | 0.220 |
Why?
|
| Forkhead Transcription Factors | 2 | 2016 | 360 | 0.210 |
Why?
|
| Cellular Senescence | 1 | 2024 | 163 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 509 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2022 | 1157 | 0.200 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2007 | 538 | 0.200 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2022 | 7 | 0.200 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 1240 | 0.200 |
Why?
|
| Neoplasm Grading | 3 | 2018 | 276 | 0.190 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2022 | 63 | 0.190 |
Why?
|
| Lymphocyte Subsets | 1 | 2022 | 38 | 0.190 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2015 | 91 | 0.190 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2025 | 559 | 0.190 |
Why?
|
| Germany | 1 | 2021 | 66 | 0.190 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 288 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 2 | 2018 | 15 | 0.190 |
Why?
|
| Primary Myelofibrosis | 1 | 2022 | 48 | 0.190 |
Why?
|
| Neoplastic Stem Cells | 1 | 2024 | 321 | 0.180 |
Why?
|
| Arginine | 1 | 2024 | 335 | 0.180 |
Why?
|
| Child | 15 | 2023 | 24613 | 0.180 |
Why?
|
| Survival Rate | 6 | 2018 | 2050 | 0.180 |
Why?
|
| Postoperative Care | 2 | 2016 | 301 | 0.180 |
Why?
|
| Cyclosporine | 2 | 2014 | 145 | 0.180 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 565 | 0.180 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2022 | 146 | 0.170 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2011 | 27 | 0.170 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 5171 | 0.170 |
Why?
|
| Leukemia, Experimental | 1 | 2020 | 15 | 0.170 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2018 | 128 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 5 | 2016 | 1026 | 0.160 |
Why?
|
| Blood Transfusion | 1 | 2002 | 311 | 0.160 |
Why?
|
| Thalidomide | 1 | 2020 | 35 | 0.160 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2020 | 52 | 0.160 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2020 | 74 | 0.160 |
Why?
|
| Donor Selection | 2 | 2019 | 54 | 0.160 |
Why?
|
| Receptors, CXCR5 | 2 | 2016 | 5 | 0.160 |
Why?
|
| Hemoglobinopathies | 1 | 2019 | 16 | 0.160 |
Why?
|
| Postoperative Complications | 3 | 2020 | 3056 | 0.160 |
Why?
|
| Machine Learning | 1 | 2022 | 251 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2019 | 61 | 0.150 |
Why?
|
| Transplantation Immunology | 3 | 2016 | 53 | 0.150 |
Why?
|
| Nephrocalcinosis | 1 | 2018 | 8 | 0.150 |
Why?
|
| Rituximab | 3 | 2015 | 152 | 0.150 |
Why?
|
| HIV-2 | 2 | 1995 | 8 | 0.150 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 75 | 0.150 |
Why?
|
| Transcriptome | 2 | 2022 | 977 | 0.150 |
Why?
|
| Hypercalcemia | 1 | 2018 | 40 | 0.150 |
Why?
|
| Gene Expression | 4 | 2018 | 1554 | 0.150 |
Why?
|
| HLA-DP beta-Chains | 1 | 2018 | 9 | 0.150 |
Why?
|
| Telomere Homeostasis | 1 | 2018 | 44 | 0.150 |
Why?
|
| HLA-DRB1 Chains | 1 | 2018 | 38 | 0.150 |
Why?
|
| Skin Transplantation | 2 | 2013 | 60 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 1692 | 0.150 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 177 | 0.150 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 1172 | 0.150 |
Why?
|
| Leukocyte Common Antigens | 2 | 2015 | 91 | 0.150 |
Why?
|
| Neoplasms | 4 | 2017 | 2799 | 0.150 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 61 | 0.140 |
Why?
|
| Ipilimumab | 1 | 2018 | 63 | 0.140 |
Why?
|
| Siblings | 2 | 2019 | 186 | 0.140 |
Why?
|
| Prognosis | 3 | 2022 | 4686 | 0.140 |
Why?
|
| Telomerase | 1 | 2018 | 169 | 0.140 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 71 | 0.140 |
Why?
|
| Mice, Knockout | 6 | 2025 | 3754 | 0.140 |
Why?
|
| Consensus | 4 | 2023 | 644 | 0.140 |
Why?
|
| Receptors, Immunologic | 1 | 2017 | 114 | 0.140 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 129 | 0.140 |
Why?
|
| Pancreatitis-Associated Proteins | 1 | 2017 | 10 | 0.140 |
Why?
|
| Cytomegalovirus Infections | 2 | 2016 | 223 | 0.140 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2017 | 16 | 0.140 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2017 | 38 | 0.140 |
Why?
|
| Metabolic Diseases | 1 | 2018 | 130 | 0.140 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2017 | 31 | 0.140 |
Why?
|
| Dogs | 1 | 2018 | 773 | 0.140 |
Why?
|
| Growth Disorders | 1 | 2018 | 209 | 0.130 |
Why?
|
| DNA-Binding Proteins | 1 | 2025 | 2061 | 0.130 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2017 | 45 | 0.130 |
Why?
|
| Proteins | 1 | 2022 | 1039 | 0.130 |
Why?
|
| Salvage Therapy | 4 | 2012 | 185 | 0.130 |
Why?
|
| Gene Products, rev | 2 | 1996 | 11 | 0.130 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2018 | 205 | 0.130 |
Why?
|
| Antigens, Neoplasm | 3 | 2019 | 384 | 0.130 |
Why?
|
| Child, Preschool | 12 | 2023 | 14149 | 0.130 |
Why?
|
| Radioimmunotherapy | 1 | 2015 | 2 | 0.130 |
Why?
|
| Pyridones | 1 | 2017 | 118 | 0.130 |
Why?
|
| Drug Administration Schedule | 4 | 2012 | 730 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 3 | 2012 | 331 | 0.120 |
Why?
|
| Virus Replication | 3 | 1996 | 607 | 0.120 |
Why?
|
| rho-Associated Kinases | 1 | 2016 | 53 | 0.120 |
Why?
|
| Immunoconjugates | 1 | 2015 | 38 | 0.120 |
Why?
|
| Flow Cytometry | 4 | 2015 | 802 | 0.120 |
Why?
|
| Skin Diseases | 1 | 2017 | 129 | 0.120 |
Why?
|
| Antigens, CD34 | 1 | 2015 | 106 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 260 | 0.120 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2008 | 69 | 0.120 |
Why?
|
| Antibodies | 1 | 2017 | 374 | 0.120 |
Why?
|
| Receptors, IgG | 1 | 2015 | 59 | 0.120 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 235 | 0.120 |
Why?
|
| Gene Products, tat | 1 | 1995 | 27 | 0.120 |
Why?
|
| Pyrimidines | 2 | 2015 | 377 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2015 | 121 | 0.110 |
Why?
|
| Lymphoid Tissue | 1 | 2014 | 47 | 0.110 |
Why?
|
| Benzodiazepines | 1 | 1995 | 102 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 465 | 0.110 |
Why?
|
| Neoplasm, Residual | 1 | 2014 | 121 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 214 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 1756 | 0.110 |
Why?
|
| Incidence | 4 | 2017 | 3134 | 0.110 |
Why?
|
| Trans-Activators | 1 | 2017 | 801 | 0.110 |
Why?
|
| Transplantation, Isogeneic | 3 | 2016 | 14 | 0.110 |
Why?
|
| HIV | 1 | 1995 | 181 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 681 | 0.110 |
Why?
|
| Pyrroles | 1 | 1995 | 184 | 0.100 |
Why?
|
| Bayes Theorem | 1 | 2014 | 286 | 0.100 |
Why?
|
| Macrophages | 1 | 2017 | 626 | 0.100 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2012 | 21 | 0.100 |
Why?
|
| Histiocytic Sarcoma | 1 | 2012 | 4 | 0.100 |
Why?
|
| Monocytes | 1 | 1995 | 345 | 0.100 |
Why?
|
| Mice, Inbred DBA | 2 | 2002 | 49 | 0.100 |
Why?
|
| Mycophenolic Acid | 2 | 2012 | 49 | 0.100 |
Why?
|
| Models, Animal | 3 | 2016 | 456 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 561 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2014 | 306 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 682 | 0.100 |
Why?
|
| DNA Methylation | 2 | 2018 | 1051 | 0.090 |
Why?
|
| Apoptosis | 1 | 2018 | 1818 | 0.090 |
Why?
|
| Recombinant Proteins | 3 | 2008 | 1400 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 544 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 630 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2024 | 3420 | 0.090 |
Why?
|
| Desensitization, Immunologic | 1 | 2013 | 103 | 0.090 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2011 | 23 | 0.090 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2019 | 66 | 0.090 |
Why?
|
| Azacitidine | 1 | 2010 | 54 | 0.090 |
Why?
|
| Transplantation, Autologous | 2 | 2009 | 272 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1982 | 0.080 |
Why?
|
| United States | 2 | 2021 | 10908 | 0.080 |
Why?
|
| Myeloproliferative Disorders | 1 | 2010 | 88 | 0.080 |
Why?
|
| Feasibility Studies | 3 | 2020 | 762 | 0.080 |
Why?
|
| Risk Factors | 4 | 2017 | 10298 | 0.080 |
Why?
|
| Lymphoma, Follicular | 1 | 2009 | 26 | 0.080 |
Why?
|
| Mutation | 2 | 2021 | 5905 | 0.080 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 60 | 0.080 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2008 | 7 | 0.080 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 384 | 0.080 |
Why?
|
| Filgrastim | 1 | 2008 | 12 | 0.080 |
Why?
|
| HIV Infections | 1 | 2020 | 1896 | 0.070 |
Why?
|
| DNA Damage | 2 | 2024 | 516 | 0.070 |
Why?
|
| Blood Component Transfusion | 1 | 2008 | 57 | 0.070 |
Why?
|
| Infant | 7 | 2020 | 12602 | 0.070 |
Why?
|
| Graft vs Tumor Effect | 1 | 2007 | 6 | 0.070 |
Why?
|
| Interleukin-2 | 3 | 2016 | 244 | 0.070 |
Why?
|
| Secondary Prevention | 3 | 2016 | 216 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2009 | 433 | 0.070 |
Why?
|
| Mice, Mutant Strains | 2 | 2019 | 385 | 0.070 |
Why?
|
| Cytokines | 3 | 2018 | 1291 | 0.070 |
Why?
|
| Aminoquinolines | 1 | 2006 | 35 | 0.070 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 309 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 706 | 0.070 |
Why?
|
| Transplants | 1 | 2006 | 34 | 0.060 |
Why?
|
| Enzyme Inhibitors | 2 | 2022 | 587 | 0.060 |
Why?
|
| Etoposide | 2 | 2020 | 115 | 0.060 |
Why?
|
| Living Donors | 1 | 2006 | 113 | 0.060 |
Why?
|
| Disease Progression | 3 | 2016 | 2084 | 0.060 |
Why?
|
| Lymphocyte Count | 2 | 2017 | 118 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2016 | 155 | 0.060 |
Why?
|
| Homeostasis | 1 | 2009 | 705 | 0.060 |
Why?
|
| Hematopoiesis | 2 | 2009 | 215 | 0.060 |
Why?
|
| Risk | 2 | 2017 | 759 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2006 | 378 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 381 | 0.060 |
Why?
|
| Methylation | 1 | 2024 | 224 | 0.050 |
Why?
|
| Skin | 1 | 2006 | 521 | 0.050 |
Why?
|
| Interferon Type I | 1 | 2024 | 108 | 0.050 |
Why?
|
| Biology | 1 | 2023 | 30 | 0.050 |
Why?
|
| Pulmonary Fibrosis | 2 | 2017 | 109 | 0.050 |
Why?
|
| Age Factors | 2 | 2015 | 2818 | 0.050 |
Why?
|
| Transfection | 2 | 1995 | 1076 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2015 | 461 | 0.050 |
Why?
|
| Cell Separation | 2 | 2015 | 230 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2017 | 3431 | 0.050 |
Why?
|
| Medicine in the Arts | 1 | 2002 | 9 | 0.050 |
Why?
|
| Mice, Inbred AKR | 1 | 2001 | 14 | 0.050 |
Why?
|
| Mice, Inbred C3H | 1 | 2001 | 113 | 0.050 |
Why?
|
| HIV-1 | 2 | 1996 | 464 | 0.050 |
Why?
|
| Cell Survival | 1 | 2024 | 821 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 1362 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2022 | 173 | 0.050 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2002 | 139 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2019 | 3044 | 0.050 |
Why?
|
| Cell Count | 1 | 2002 | 252 | 0.050 |
Why?
|
| North America | 1 | 2002 | 243 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2002 | 586 | 0.050 |
Why?
|
| Piperidines | 2 | 2014 | 208 | 0.040 |
Why?
|
| Europe | 1 | 2002 | 359 | 0.040 |
Why?
|
| Patient Selection | 2 | 2015 | 696 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2019 | 2813 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 1077 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2021 | 78 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 133 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2011 | 60 | 0.040 |
Why?
|
| Medically Underserved Area | 1 | 2021 | 89 | 0.040 |
Why?
|
| Alemtuzumab | 2 | 2012 | 86 | 0.040 |
Why?
|
| Forecasting | 1 | 2002 | 352 | 0.040 |
Why?
|
| Interferon-gamma | 2 | 2016 | 505 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2023 | 321 | 0.040 |
Why?
|
| Hexosamines | 1 | 2020 | 16 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2021 | 257 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 42 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2020 | 163 | 0.040 |
Why?
|
| Spleen | 2 | 2016 | 281 | 0.040 |
Why?
|
| Scleroderma, Localized | 1 | 2019 | 7 | 0.040 |
Why?
|
| Minority Groups | 1 | 2021 | 243 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2012 | 772 | 0.040 |
Why?
|
| Receptors, OX40 | 1 | 2018 | 7 | 0.040 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2019 | 63 | 0.040 |
Why?
|
| rev Gene Products, Human Immunodeficiency Virus | 2 | 1996 | 17 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2019 | 84 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2001 | 505 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 262 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 1275 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2018 | 114 | 0.040 |
Why?
|
| Syndrome | 2 | 2014 | 1121 | 0.040 |
Why?
|
| Viral Load | 1 | 2020 | 388 | 0.040 |
Why?
|
| Safety | 1 | 2019 | 217 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 143 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2009 | 4595 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 733 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2019 | 220 | 0.030 |
Why?
|
| Models, Immunological | 1 | 2016 | 36 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2018 | 240 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2017 | 63 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 125 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2017 | 121 | 0.030 |
Why?
|
| RNA, Catalytic | 1 | 1996 | 15 | 0.030 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2016 | 52 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2016 | 10 | 0.030 |
Why?
|
| San Francisco | 1 | 2016 | 17 | 0.030 |
Why?
|
| Histocompatibility Antigen H-2D | 1 | 2015 | 3 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 875 | 0.030 |
Why?
|
| Karyotyping | 1 | 2016 | 323 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 426 | 0.030 |
Why?
|
| Genes, rev | 1 | 1995 | 5 | 0.030 |
Why?
|
| Weight Loss | 1 | 2019 | 482 | 0.030 |
Why?
|
| Baltimore | 1 | 2015 | 14 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1995 | 190 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2015 | 118 | 0.030 |
Why?
|
| Syk Kinase | 1 | 2015 | 16 | 0.030 |
Why?
|
| Cell Nucleolus | 1 | 1995 | 56 | 0.030 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2017 | 223 | 0.030 |
Why?
|
| Oxazines | 1 | 2015 | 25 | 0.030 |
Why?
|
| Drug Antagonism | 1 | 1995 | 12 | 0.030 |
Why?
|
| Defective Viruses | 1 | 1995 | 18 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1995 | 70 | 0.030 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 1995 | 30 | 0.030 |
Why?
|
| Morpholines | 1 | 2015 | 59 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2016 | 224 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2015 | 57 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 325 | 0.030 |
Why?
|
| Fibrosis | 1 | 2016 | 442 | 0.030 |
Why?
|
| Receptors, Interleukin-21 | 1 | 2014 | 1 | 0.030 |
Why?
|
| Genome, Viral | 1 | 1995 | 166 | 0.030 |
Why?
|
| Inducible T-Cell Co-Stimulator Ligand | 1 | 2014 | 4 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 1434 | 0.030 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2014 | 8 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2014 | 37 | 0.030 |
Why?
|
| DNA Primers | 1 | 1995 | 657 | 0.030 |
Why?
|
| CD40 Antigens | 1 | 2014 | 25 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 366 | 0.030 |
Why?
|
| Adenine | 1 | 2014 | 104 | 0.030 |
Why?
|
| Base Sequence | 2 | 1996 | 3111 | 0.030 |
Why?
|
| CD40 Ligand | 1 | 2014 | 62 | 0.030 |
Why?
|
| ABO Blood-Group System | 1 | 2014 | 66 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 360 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2015 | 350 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2016 | 491 | 0.030 |
Why?
|
| RNA, Viral | 1 | 1996 | 538 | 0.030 |
Why?
|
| HeLa Cells | 1 | 1995 | 808 | 0.030 |
Why?
|
| Pyridines | 1 | 2015 | 235 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 375 | 0.030 |
Why?
|
| Viral Proteins | 1 | 1995 | 347 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 3900 | 0.030 |
Why?
|
| Interleukins | 1 | 2014 | 120 | 0.030 |
Why?
|
| Pentostatin | 1 | 2012 | 11 | 0.030 |
Why?
|
| Diphtheria Toxin | 1 | 2012 | 12 | 0.030 |
Why?
|
| Cell Line | 2 | 1996 | 2756 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2014 | 174 | 0.030 |
Why?
|
| Etanercept | 1 | 2012 | 40 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1172 | 0.030 |
Why?
|
| Wound Healing | 1 | 2016 | 460 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 70 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 351 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2013 | 227 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 299 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2880 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2013 | 145 | 0.020 |
Why?
|
| Lymphotoxin beta Receptor | 1 | 2011 | 1 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2011 | 2414 | 0.020 |
Why?
|
| Mice, 129 Strain | 1 | 2011 | 97 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 1995 | 1592 | 0.020 |
Why?
|
| Blood Donors | 1 | 2011 | 59 | 0.020 |
Why?
|
| Aging | 1 | 2018 | 1182 | 0.020 |
Why?
|
| Mitoxantrone | 1 | 2010 | 26 | 0.020 |
Why?
|
| Daunorubicin | 1 | 2010 | 27 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2012 | 430 | 0.020 |
Why?
|
| Cytosine | 1 | 2010 | 57 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 2373 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2016 | 8273 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 184 | 0.020 |
Why?
|
| Flavonoids | 1 | 2010 | 77 | 0.020 |
Why?
|
| Neutropenia | 1 | 2011 | 199 | 0.020 |
Why?
|
| Inflammation | 1 | 2016 | 1445 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2009 | 256 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 1275 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1320 | 0.020 |
Why?
|
| Fever | 1 | 2011 | 300 | 0.020 |
Why?
|
| Lung | 1 | 2016 | 1491 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1294 | 0.020 |
Why?
|
| Cause of Death | 1 | 2009 | 473 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 362 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2656 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 2909 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 1427 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2011 | 859 | 0.010 |
Why?
|
| Hospitalization | 1 | 2011 | 1791 | 0.010 |
Why?
|
| Nuclear Family | 1 | 2002 | 49 | 0.010 |
Why?
|
| Reticulocyte Count | 1 | 2001 | 2 | 0.010 |
Why?
|
| Hemoglobin, Sickle | 1 | 2001 | 20 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2001 | 250 | 0.010 |
Why?
|
| Linear Models | 1 | 2001 | 683 | 0.010 |
Why?
|
| Pregnancy | 1 | 2009 | 7226 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 898 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1996 | 478 | 0.010 |
Why?
|
| Liver | 1 | 2001 | 1749 | 0.010 |
Why?
|